1 not yet recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Systemic Therapy: new trials by email Literature Review of Systemic Therapy trials Research Report on Systemic Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Antibody-Drug Conjugate Plus Immunotherapy Versus Immunotherapy Plus Chemotherapy for Extensive Transurethrally Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer Disitamab Vedotin and Toripalimab, Toripalimab and Nab-Paclitaxel - Bladder (Urothelial, Transitional Cell) Cancer, Antibody-drug Conjugates | Phase 2 | Not yet recruiting | Tianjin Medical University Second Hospital | 150 | 2026-10-20 | 2026-10-23 |
Neoplasms (1)
130-nm albumin-bound paclitaxel (1) · disitamab vedotin (1) · toripalimab (1)
Tianjin Medical University Second Hospital (1)
China (1)